An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation
← catalyst calendarNCT07041606 · readout in 315 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
500estimated
Sites
19
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-24 | actual | When the study began enrolling |
| Primary completion | 2027-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Endometrial Cancer
Primary outcomes
what the primary-completion date above is the date OFThe rate of POLEm positive status
measured 24 months
The rate of dMMR status and pMMR status detected by IHC and by combined approach of molecular classification
measured 24 months
The rate of p53abn positive status detected by IHC and by combined approach of molecular classification
measured 24 months
The rate of PD-L1 positive status detected by IHC
measured 24 months
The rate of HER2 expression 3+ detected by IHC
measured 24 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed